Outcomes18

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

1 to 18 of 18

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Percentage of Participants With Grade II-IV Acute Graft Versus Host Disease (GVHD)	6 months	2 of 44 patients who completed the AC arm were transplanted after our cutoff for data analysis and are not included.	percentage of participants	NUMBER
PRIMARY	Percentage of Participants With Chronic Graft Versus Host Disease (cGVHD)	2 years post transplant	2 of 44 patients who completed the AC arm were transplanted after our cutoff for data analysis and are not included.	percentage of participants	NUMBER
PRIMARY	Recovery of Naïve Cluster of Differentiation 4 (CD4) T Cells	Recipient recovery at 6, 12 and 24 months post transplant	A few measurements were missed, one patient was not evaluable for technical reasons and removed from the analysis, but most of the decline was due to patients that had gone off study.	% of naive (CCR7+CD45RA+) CD4 Cells	MEDIAN
PRIMARY	Recovery of Naïve Cluster of Differentiation 8 (CD8) T Cells	Recipient recovery at 6, 12 and 24 months post transplant	A few measurements were missed, one patient was not evaluable for technical reasons and removed from the analysis, but most of the decline was due to patients that had gone off study.	% of naive (CCR7+CD45RA+) CD8 Cells	MEDIAN
PRIMARY	Changes in Cluster of Differentiation 4 (CD4) T Cell Receptor Vbeta Repertoire	Donor at time of collection and recipient at 1, 3, 6 and 12 months post transplant	The original intention was to perform these assays on the first 10 pts within each arm. One pt died within the first mo., others died within the 1st yr. Not all donors gave consent for research analyses to be done on their cells, hence cells from those donors were not available.	Divergence index	MEDIAN
PRIMARY	Changes in CD8 T Cell Receptor Vbeta Repertoire	Donor at time of collection and recipient at 1, 3, 6 and 12 months post transplant	The original intention was to perform these assays on the first 10 pts within each arm. One pt died within the first mo., others died within the 1st yr. Not all donors gave consent for research analyses to be done on their cells, hence cells from those donors were not available.	Divergence index	MEDIAN
SECONDARY	Percentage of Participants With Grade III-IV Acute Graft Versus Host Disease (GVHD)	6 months	2 of 44 patients who completed the AC arm were transplanted after our cutoff for data analysis and are not included.	percentage of participants	NUMBER
SECONDARY	Toxicities	103 months and 22 days		participants	NUMBER
SECONDARY	Days to Engraftment of Neutrophils	2 years	One myeloma patient had graft failure in the AC Arm. 2 of 44 patients who completed the AC arm were transplanted after our cutoff for data analysis and are not included.	Days to neutrophil engraftment	MEDIAN
SECONDARY	Days to Engraftment of Platelets	2 years	2 of 44 patients who completed the AC arm were transplanted after our cutoff for data analysis and are not included.	Days	MEDIAN
SECONDARY	Days to Engraftment of Lymphocytes	2 years	2 of 44 patients who completed the AC arm were transplanted after our cutoff for data analysis and are not included.	Days	MEDIAN
SECONDARY	Overall Survival	Patients were followed for an average of up to 5 years.	2 of 44 patients who completed the AC arm were transplanted after our cutoff for data analysis and are not included.	Months	MEDIAN
SECONDARY	Early Treatment Related Mortality	Less than or equal to 28 days after transplantation	2 of 44 patients who completed the AC arm were transplanted after our cutoff for data analysis and are not included.	participants	NUMBER
SECONDARY	Percentage of Participants With Late Treatment Related Mortality	Greater than 28 days after transplantation	2 of 44 patients who completed the AC arm were transplanted after our cutoff for data analysis and are not included.	percentage of participants	NUMBER
SECONDARY	Decline in Homeostatic Cytokine Interleukin 7 (IL-7) Post-Transplant	Day 0, 1 week and 2 weeks	Following the focus on chronic graft-versus host disease (GVHD) as a primary outcome measure in 2011, this measure was not assessed.
SECONDARY	Immune Reconstitution of Normal Killer (NK) Cells	2 weeks, and 1, 3, 6, 12, and 24 months post transplant	2 of 44 patients who completed the AC arm were transplanted after our cutoff for data analysis and are not included. A total of 5 completed participants did not contribute data due to missing samples, and participants who died and were not able to supply samples for the time points indicated.	Cells/µl	MEDIAN
SECONDARY	Immune Reconstitution of Cluster of Differentiation 4 (CD4) T Cell Populations	2 weeks, and 1, 3, 6, 12 and 24 months post transplant	2 of 44 patients who completed the AC arm were transplanted after our cutoff for data analysis and are not included. A total of 5 completed participants did not contribute data due to missing samples, and participants who died and were not able to supply samples for the time points indicated.	Cells/µl	MEDIAN
SECONDARY	Immune Reconstitution of Cluster of Differentiation 8 (CD8) T Cell Populations	2 weeks, 1, 3, 6, 12 and 24 months post transplant	2 of 44 patients who completed the AC arm were transplanted after our cutoff for data analysis and are not included. A total of 5 completed participants did not contribute data due to missing samples, and participants who died and were not able to supply samples for the time points indicated.	Cells/µl	MEDIAN

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00520130/outcomes

API reference For AI assistants